Cancer Research and Treatment

Original Articles

Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib: Jeong-Ju Yoo, Goh Eun Chung, Jeong-Hoon Lee, Joon Yeul Nam, Young Chang, Jeong Min Lee, Dong Ho Lee, Hwi Young Kim, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Seoul Liver Group; Cancer Res Treat. 2018;50(2):366-373. Published online May 15, 2017; DOI: https://doi.org/10.4143/crt.2017.126

Purpose
Advanced hepatocellular carcinoma (HCC) is associated with various clinical conditions including major vessel invasion, metastasis, and poor performance status. The aim of this study was to establish a prognostic scoring system and to propose a sub-classification of the Barcelona-Clinic Liver Cancer (BCLC) stage C.
Materials and Methods
This retrospective study included consecutive patientswho received sorafenib for BCLC stage C HCC at a single tertiary hospital in Korea. A Cox proportional hazard model was used to develop a scoring system, and internal validationwas performed by a 5-fold cross-validation. The performance of the model in predicting risk was assessed by the area under the curve and the Hosmer-Lemeshow test.
Results
A total of 612 BCLC stage C HCC patients were sub- classified into strata depending on their performance status. Five independent prognostic factors (Child-Pugh score, α-fetoprotein, tumor type, extrahepatic metastasis, and portal vein invasion) were identified and used in the prognostic scoring system. This scoring system showed good discrimination (area under the receiver operating characteristic curve, 0.734 to 0.818) and calibration functions (both p < 0.05 by the Hosmer-Lemeshow test at 1 month and 12 months, respectively). The differences in survival among the different risk groups classified by the total score were significant (p < 0.001 by the log-rank test in both the Eastern Cooperative Oncology Group 0 and 1 strata).
Conclusion
The heterogeneity of patientswith BCLC stage C HCC requires sub-classification of advanced HCC. A prognostic scoring system with five independent factors is useful in predicting the survival of patients with BCLC stage C HCC.

Citations

Citations to this article as recorded by

Tumor burden affects the progression pattern on the prognosis in patients treated with sorafenib
Jun Sun, Dongdong Xia, Wei Bai, Xiaomei Li, Enxing Wang, ZhanXin Yin, Guohong Han
Frontiers in Oncology.2024;[Epub] CrossRef
A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Ji W. Han, Soon K. Lee, Jung H. Kwon, Soon W. Nam, Hyun Yang, Si H. Bae, Ji H. Kim, Heechul Nam, Chang W. Kim, Hae L. Lee, Hee Y. Kim, Sung W. Lee, Ahlim Lee, U I. Chang, Do S. Song, Seok-Hwan Kim, Myeong J. Song, Pil S. Sung, Jong Y. Choi, Seung K. Yoon,
Clinical Cancer Research.2024; 30(13): 2812. CrossRef
Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment
Sujin Jin, Won-Mook Choi, Ju Hyun Shim, Danbi Lee, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jinhong Jung, Sang Min Yoon, Jonggi Choi
Journal of Liver Cancer.2023; 23(1): 177. CrossRef
Development and validation of web‐based prognostic nomograms for massive hepatocellular carcinoma (≥10 cm): A retrospective study based on the SEER database
Guizhong Huang, Qiaohong Lin, Pengfei Yin, Kai Mao, Jianlong Zhang
Cancer Medicine.2023; 12(12): 13167. CrossRef
Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma
Xiaomi Li, Xiaoyan Ding, Mei Liu, Jingyan Wang, Wei Li, Jinglong Chen
The Oncologist.2023; 28(10): e942. CrossRef
Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: a systematic review and critical appraisal
Li Li, Xiaomi Li, Wendong Li, Xiaoyan Ding, Yongchao Zhang, Jinglong Chen, Wei Li
BMC Cancer.2022;[Epub] CrossRef
Identification and validation of a prognostic model of necroptosis-related lncRNAs in hepatocellular carcinoma
Min Chen, Guang-Bo Wu, Shan Hua, Zhi-Feng Zhao, Hong-Jie Li, Meng Luo
Frontiers in Genetics.2022;[Epub] CrossRef
Prognostic value of a nomogram based on peripheral blood immune parameters in unresectable hepatocellular carcinoma after intensity-modulated radiotherapy
Jian-Xu Li, Mei-Ling He, Mo-Qin Qiu, Liu-Ying Yan, Mei-Ying Long, Jian-Hong Zhong, Rui-Jun Zhang, Chun-Feng Liang, Ya-Dan Pang, Jun-Kun He, Qian-Qian Chen, Jin-Xia Weng, Shi-Xiong Liang, Bang-De Xiang
BMC Gastroenterology.2022;[Epub] CrossRef
A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study
Giovanni Marasco, Francesco Poggioli, Antonio Colecchia, Giuseppe Cabibbo, Filippo Pelizzaro, Edoardo Giannini, Sara Marinelli, Gian Rapaccini, Eugenio Caturelli, Mariella Di Marco, Elisabetta Biasini, Fabio Marra, Filomena Morisco, Francesco Foschi, Marc
Cancers.2021; 13(11): 2677. CrossRef
Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study
Young Youn Cho, Su Jong Yu, Hye Won Lee, Do Young Kim, Wonseok Kang, Yong-Han Paik, Pil Soo Sung, Si Hyun Bae, Su Cheol Park, Young Seok Doh, Kang Mo Kim, Eun Sun Jang, In Hee Kim, Won Kim, Yoon Jun Kim
Journal of Hepatocellular Carcinoma.2021; Volume 8: 613. CrossRef
Identification and Validation of a Prognostic Prediction Model of m6A Regulator-Related LncRNAs in Hepatocellular Carcinoma
Chen Jin, Rui Li, Tuo Deng, Jialiang Li, Yan Yang, Haoqi Li, Kaiyu Chen, Huihua Xiong, Gang Chen, Yi Wang
Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
Construction and validation of an N6‑methyladenosine‑associated prognostic signature in hepatocellular carcinoma
Peng Zhu, Qianqian Ren, Nan He, Cheng Zhou, Qianna Jin, Zhao Gong
Oncology Letters.2021;[Epub] CrossRef
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
Tim A. Labeur, Sarah Berhane, Julien Edeline, Jean‐Frederic Blanc, Dominik Bettinger, Tim Meyer, Jeroen L. A. Van Vugt, David W. G. Ten Cate, Robert A. De Man, Ferry A. L. M. Eskens, Alessandro Cucchetti, Laura J. Bonnett, Otto M. Van Delden, Heinz‐Josef
Liver International.2020; 40(1): 215. CrossRef
A novel prognostic score model based on combining systemic and hepatic inflammation markers in the prognosis of HBV-associated hepatocellular carcinoma patients
Tingting Zhang, Zhe Liu, Xiangqian Zhao, Zhiyuan Mao, Li Bai
Artificial Cells, Nanomedicine, and Biotechnology.2019; 47(1): 2246. CrossRef
Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C
Yeon Joo Kim, Jinhong Jung, Ji Hyeon Joo, So Yeon Kim, Jin Hyoung Kim, Young-Suk Lim, Han Chu Lee, Jong Hoon Kim, Sang Min Yoon
Radiotherapy and Oncology.2019; 141: 95. CrossRef
Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation
Bo Hyun Kim, Joong-Won Park
Journal of Korean Medical Science.2018;[Epub] CrossRef

11,015 View
309 Download
18 Web of Science
16 Crossref

Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data: Do Young Kim, Hye Jin Kim, Kwang-Hyub Han, Sang Young Han, Jeong Heo, Hyun Young Woo, Soon Ho Um, Yeul Hong Kim, Young Oh Kweon, Ho Yeong Lim, Jung Hwan Yoon, Wan Sik Lee, Byung Seok Lee, Han Chu Lee, Baek-Yeol Ryoo, Seung Kew Yoon; Cancer Res Treat. 2016;48(4):1243-1252. Published online February 24, 2016; DOI: https://doi.org/10.4143/crt.2015.278

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to report real life experiences of sorafenib therapy for hepatocellular carcinoma (HCC) in Korea, using a subset of data from GIDEON (Global Investigation of Therapeutic Decisions in HCC and of Its Treatment with Sorafenib; a large, prospective, observational study).
Materials and Methods
Between January 2009 and April 2012, a total of 497 patients were enrolled from 11 sites in Korea. Of these, 482 patients were evaluable for safety analyses. Case report forms of paper or electronic version were used to record safety and efficacy data from all patients.
Results
More patients of Child-Pugh A received sorafenib for > 8 weeks than did patients of Child-Pugh B (55.5% vs. 34.3%). Child-Pugh score did not appear to influence the starting dose of sorafenib, and approximately 70% of patients both in Child-Pugh A and B groups received the recommended initial daily dose of 800 mg (69.0% and 69.5%, respectively). The median overall survival (OS) and time to progression (TTP) were 8.5 months and 2.5 months. In Child-Pugh A patients, the median OS and TTP were 10.2 months and 2.5 months. The most frequent treatment-emergent drug-related adverse event was hand-foot skin reaction (31.7%), followed by diarrhea (18.0%). The incidence of treatment-emergent adverse events was similar in both Child-Pugh A (85.4%) and Child-Pugh B (84.8%) patients.
Conclusion
Sorafenib was well tolerated by Korean HCC patients in clinical settings, and the safety profile did not appear to differ by Child-Pugh status. Survival benefit in Korean patients was in line with that of a previous pivotal phase III trial (SHARP).

Citations

Citations to this article as recorded by

Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study
Christian Möhring, Moritz Berger, Farsaneh Sadeghlar, Xin Zhou, Taotao Zhou, Malte Benedikt Monin, Kateryna Shmanko, Sabrina Welland, Friedrich Sinner, Birgit Schwacha-Eipper, Ulrike Bauer, Christoph Roderburg, Angelo Pirozzi, Najib Ben Khaled, Peter Schr
Cancers.2025; 17(6): 972. CrossRef
Real-World Comparison of Lenvatinib and Sorafenib as First-Line Treatments for Hepatocellular Carcinoma: A Multicenter Study
Mira Kang, Won Chul Cha, Dong Hyun Sinn, Woo Kyoung Jeong, Do Young Kim, Min Ji Lee, Subin Lim, DongKyu Kim, Kyu-Pyo Kim, Baek-Yeol Ryoo, Won-Mook Choi, Kang Mo Kim, Ki-Hun Kim, Doik Lee, Eui Jun Choi, Choungwon Jung, Joohyun Kim, Jung Yong Hong
Journal of Hepatocellular Carcinoma.2025; Volume 12: 2611. CrossRef
Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea
Sojung Han, Do Young Kim, Ho Yeong Lim, Jung-Hwan Yoon, Baek-Yeol Ryoo, Yujeong Kim, Kookhee Kim, Bo Yeon Kim, So Young Yi, Dong-Sook Kim, Do-Yeon Cho, Jina Yu, Suhyun Kim, Joong-Won Park
Gut and Liver.2024; 18(1): 116. CrossRef
Locoregional treatment improves overall survival for liver cancer during second-line regorafenib or immune checkpoint inhibitor
Po-Ting Lin
American Journal of Cancer Research.2024; 14(3): 1306. CrossRef
Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review
Florian P. Reiter, Najib Ben Khaled, Liangtao Ye, Changhua Zhang, Max Seidensticker, Mark op den Winkel, Gerald Denk, Andreas Geier, Enrico N. De Toni
Digestive Diseases.2022; 40(5): 565. CrossRef
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123. CrossRef
Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research
Francesca Negri, Gabriele Missale, Anna Degli Antoni, Camillo Porta
Translational Oncology.2021; 14(9): 101153. CrossRef
Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial
Beom Kyung Kim, Do Young Kim, Hwa Kyung Byun, Hye Jin Choi, Seung-Hoon Beom, Hye Won Lee, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Jinsil Seong, Kwang-Hyub Han
International Journal of Radiation Oncology*Biology*Physics.2020; 107(1): 106. CrossRef
Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin
Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Jong Yul Lee, Young Woon Kim, Dong Jae Shim, Sung Won Lee, Jeong Won Jang
Cancer Control.2020;[Epub] CrossRef
Hepatocellular Carcinoma in Korea between 2012 and 2014: an Analysis of Data from the Korean Nationwide Cancer Registry
Young Eun Chon, Han Ah Lee, Jun Sik Yoon, Jun Yong Park, Bo Hyun Kim, In Joon Lee, Suk Kyun Hong, Dong Hyeon Lee, Hyun-Joo Kong, Eunyang Kim, Young-Joo Won, Jeong-Hoon Lee
Journal of Liver Cancer.2020; 20(2): 135. CrossRef
Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion

Sojung Han, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Dai Hoon Han, Beom Kyung Kim
Journal of Hepatocellular Carcinoma.2020; Volume 7: 403. CrossRef
Sorafenib: key lessons from over 10 years of experience
Bernard Escudier, Francis Worden, Masatoshi Kudo
Expert Review of Anticancer Therapy.2019; 19(2): 177. CrossRef
Liver Transplantation after Successful Downstaging with Hepatic Arterial Infusion Chemotherapy in a Patient with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
Hee Chul Nam, Pil Soo Sung, Ho Jong Chun, Dong Goo Kim, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon
Journal of Liver Cancer.2019; 19(1): 64. CrossRef
18F–fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment
Pil Soo Sung, Hye Lim Park, Keungmo Yang, Seawon Hwang, Myeong Jun Song, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Ie Ryung Yoo, Si Hyun Bae
European Journal of Nuclear Medicine and Molecular Imaging.2018; 45(3): 384. CrossRef
Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial
Nikhil Chauhan, Janet Bukovcan, Eveline Boucher, David Cosgrove, Julien Edeline, Bonnie Hamilton, Laura Kulik, Fayaz Master, Riad Salem
JMIR Research Protocols.2018; 7(8): e11234. CrossRef
Sorafenib: A Review in Hepatocellular Carcinoma
Gillian M. Keating
Targeted Oncology.2017; 12(2): 243. CrossRef
Treatment options after sorafenib failure in patients with hepatocellular carcinoma
Imane El Dika, Ghassan K. Abou-Alfa
Clinical and Molecular Hepatology.2017; 23(4): 273. CrossRef
Dickkopf-1 induces angiogenesis via VEGF receptor 2 regulation independent of the Wnt signaling pathway
Sung Hoon Choi, Hyemi Kim, Hyun Gyu Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
Oncotarget.2017; 8(35): 58974. CrossRef

15,531 View
311 Download
24 Web of Science
18 Crossref

First
Prev
Page of 1
Next
Last

Search